DK1105460T3 - Differentiering af ikke-insulinproducerende celler til insulinproducerende celler med GLP-1 eller Exendin-4 og anvendelser deraf - Google Patents
Differentiering af ikke-insulinproducerende celler til insulinproducerende celler med GLP-1 eller Exendin-4 og anvendelser derafInfo
- Publication number
- DK1105460T3 DK1105460T3 DK99942066.4T DK99942066T DK1105460T3 DK 1105460 T3 DK1105460 T3 DK 1105460T3 DK 99942066 T DK99942066 T DK 99942066T DK 1105460 T3 DK1105460 T3 DK 1105460T3
- Authority
- DK
- Denmark
- Prior art keywords
- producing cells
- insulin producing
- exendin
- glp
- insulin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/335—Glucagon; Glucagon-like peptide [GLP]; Exendin
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9591798P | 1998-08-10 | 1998-08-10 | |
PCT/US1999/018099 WO2000009666A2 (en) | 1998-08-10 | 1999-08-10 | Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1105460T3 true DK1105460T3 (da) | 2010-02-08 |
Family
ID=22254191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99942066.4T DK1105460T3 (da) | 1998-08-10 | 1999-08-10 | Differentiering af ikke-insulinproducerende celler til insulinproducerende celler med GLP-1 eller Exendin-4 og anvendelser deraf |
Country Status (10)
Country | Link |
---|---|
US (2) | US7056734B1 (da) |
EP (2) | EP2028269B1 (da) |
JP (4) | JP4624558B2 (da) |
AT (1) | ATE445006T1 (da) |
AU (1) | AU776514B2 (da) |
CA (1) | CA2339326A1 (da) |
DE (1) | DE69941510D1 (da) |
DK (1) | DK1105460T3 (da) |
ES (2) | ES2335066T3 (da) |
WO (1) | WO2000009666A2 (da) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7138486B2 (en) * | 1986-05-05 | 2006-11-21 | The General Hospital Corporation | Insulinotropic hormone derivatives and uses thereof |
US6703017B1 (en) | 1994-04-28 | 2004-03-09 | Ixion Biotechnology, Inc. | Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures |
US6699973B1 (en) * | 1998-11-19 | 2004-03-02 | Elan Corporation, Plc | Antibodies to peptides that target GIT receptors and related methods |
US6242666B1 (en) * | 1998-12-16 | 2001-06-05 | The Scripps Research Institute | Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells |
US6967019B2 (en) * | 1999-04-06 | 2005-11-22 | The Regents Of The University Of California | Production of pancreatic islet cells and delivery of insulin |
US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
US20030082155A1 (en) * | 1999-12-06 | 2003-05-01 | Habener Joel F. | Stem cells of the islets of langerhans and their use in treating diabetes mellitus |
US6448045B1 (en) * | 2000-03-10 | 2002-09-10 | The Regents Of The University Of California | Inducing insulin gene expression in pancreas cells expressing recombinant PDX-1 |
EP1346722B1 (en) | 2000-12-01 | 2008-12-10 | Takeda Pharmaceutical Company Limited | Method for producing preparation containing bioactive substance |
EP2022505B1 (en) | 2001-07-31 | 2011-12-14 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | GLP-1, exendin-4, peptide analogs and uses thereof |
US6642003B2 (en) * | 2001-08-02 | 2003-11-04 | Cedars-Sinai Medical Center | Human glucose-dependent insulin-secreting cell line |
US6911324B2 (en) | 2001-10-18 | 2005-06-28 | The Regents Of The University Of California | Induction of beta cell differentiation in human cells |
PL374557A1 (en) * | 2001-11-09 | 2005-10-31 | Artecel Sciences, Inc. | Endocrine pancreas differentiation of adipose tissue-derived stromal cells and uses thereof |
ES2545090T3 (es) | 2001-12-21 | 2015-09-08 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina y GCSF |
US7635463B2 (en) | 2002-02-27 | 2009-12-22 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials |
AU2003219922B2 (en) * | 2002-02-27 | 2009-09-10 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials, and methods of making and using the same |
US20050260259A1 (en) * | 2004-04-23 | 2005-11-24 | Bolotin Elijah M | Compositions for treatment with glucagon-like peptide, and methods of making and using the same |
EP1507848A4 (en) * | 2002-05-28 | 2005-11-23 | Becton Dickinson Co | EXPANSION AND TRANSDIFFERENCING OF HUMAN AZINUS CELLS |
EP1569682A2 (en) * | 2002-12-03 | 2005-09-07 | Novo Nordisk A/S | Combination treatment using exendin-4 and thiazolidinediones |
EP1688148A1 (en) * | 2002-12-03 | 2006-08-09 | Novo Nordisk A/S | Combination treatment using exendin-4 and thiazolidinediones |
WO2004069314A1 (en) | 2003-02-04 | 2004-08-19 | Novo Nordisk A/S | Injection device with rotatable dose setting |
WO2004113512A2 (en) * | 2003-06-20 | 2004-12-29 | Vrije Universiteit Brussel | Method of generating islet beta-cells from exocrine pancreatic cells |
US9592258B2 (en) | 2003-06-27 | 2017-03-14 | DePuy Synthes Products, Inc. | Treatment of neurological injury by administration of human umbilical cord tissue-derived cells |
US9572840B2 (en) | 2003-06-27 | 2017-02-21 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue using postpartum-derived cells |
US8790637B2 (en) | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
AU2004252567B2 (en) | 2003-06-27 | 2011-10-06 | Ethicon, Incorporated | Repair and regeneration of ocular tissue using postpartum-derived cells |
MXPA06007667A (es) | 2004-01-06 | 2006-09-01 | Novo Nordisk As | Heteroaril-ureas y su uso como activadores de glucocinasa. |
ES2642214T3 (es) | 2004-01-21 | 2017-11-15 | Novo Nordisk Health Care Ag | Conjugación de péptidos mediante transglutaminasa |
JPWO2005118781A1 (ja) * | 2004-06-03 | 2008-04-03 | 国立大学法人京都大学 | インスリン分泌細胞の誘導 |
US8148412B2 (en) | 2004-12-03 | 2012-04-03 | Novo Nordisk A/S | Heteroaromatic glucokinase activators |
MX2008000255A (es) | 2005-07-14 | 2008-04-02 | Novo Nordisk As | Activadores de urea glucocinasa. |
EA015169B1 (ru) | 2005-09-14 | 2011-06-30 | Такеда Фармасьютикал Компани Лимитед | Применение ингибиторов дипептидилпептидазы |
CN102675221A (zh) | 2005-09-16 | 2012-09-19 | 武田药品工业株式会社 | 用于制备嘧啶二酮衍生物的方法中的中间体 |
JP5289970B2 (ja) | 2005-12-16 | 2013-09-11 | エシコン・インコーポレイテッド | 組織適合性不適合な移植における逆免疫反応を抑制するための組成物および方法 |
JP2009520040A (ja) | 2005-12-19 | 2009-05-21 | ファーマイン コーポレーション | 治療薬の送達のための疎水性コアの担体組成物、及び同担体組成物の作製法及び使用法 |
US9125906B2 (en) | 2005-12-28 | 2015-09-08 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using umbilical cord tissue-derived cells |
EP1996224B1 (en) | 2006-03-15 | 2012-11-07 | Novo Nordisk A/S | Mixtures of amylin and insulin |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
AU2008204530B2 (en) | 2007-01-11 | 2013-08-01 | Vtv Therapeutics Llc | Urea glucokinase activators |
RU2413528C2 (ru) | 2007-01-18 | 2011-03-10 | Открытое Акционерное Общество "Валента Фармацевтика" | Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
EP2170945A1 (en) | 2007-07-16 | 2010-04-07 | Novo Nordisk A/S | Protease stabilized, pegylated insulin analogues |
US7960336B2 (en) * | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
US8563527B2 (en) * | 2007-08-20 | 2013-10-22 | Pharmain Corporation | Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same |
US20090176892A1 (en) | 2008-01-09 | 2009-07-09 | Pharmain Corporation | Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same |
EP2259791A2 (en) * | 2008-03-05 | 2010-12-15 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer |
RU2571857C2 (ru) | 2008-03-18 | 2015-12-20 | Ново Нордиск А/С | Стабилизированные по отношению к протеазам ацилированные аналоги инсулина |
JP2011526303A (ja) | 2008-06-27 | 2011-10-06 | デューク ユニバーシティ | エラスチン様ペプチドを含む治療剤 |
CA2747794C (en) | 2008-12-19 | 2018-10-30 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of lung and pulmonary diseases and disorders |
US10179900B2 (en) | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
BRPI1013409A2 (pt) | 2009-03-26 | 2018-01-16 | Advanced Tech And Regenerative Medicine Llc | células de tecido de cordão umbilical humano como terapia para doença de alzheimer |
CN101991580B (zh) * | 2009-08-28 | 2013-03-20 | 杏辉天力(杭州)药业有限公司 | 以羊毛甾烷及茯苓萃取物治疗糖尿病的用途 |
CA2782056C (en) | 2009-11-25 | 2021-03-09 | Arisgen Sa | Mucosal delivery of peptides |
SG184988A1 (en) | 2010-04-27 | 2012-11-29 | Zealand Pharma As | Peptide conjugates of glp-1 receptor agonists and gastrin and their use |
JP5866106B2 (ja) | 2010-05-12 | 2016-02-17 | コロンビア ユニヴァーシティ | インスリンを産生し分泌する腸内分泌細胞の製造方法 |
BR112014010780A2 (pt) | 2011-11-03 | 2017-04-25 | Zealand Pharma As | conjugados do peptídeo agonista do receptor glp-1-gastrina |
JP6301263B2 (ja) | 2011-12-23 | 2018-03-28 | デピュイ・シンセス・プロダクツ・インコーポレイテッド | ヒト臍帯組織由来細胞の検出 |
NZ704043A (en) | 2012-07-23 | 2017-07-28 | Zealand Pharma As | Glucagon analogues |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
AU2013366691A1 (en) | 2012-12-21 | 2015-07-09 | Sanofi | Exendin-4 derivatives |
PL3057984T3 (pl) | 2013-10-17 | 2018-12-31 | Zealand Pharma A/S | Acylowane analogi glukagonu |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
MX369770B (es) | 2013-11-06 | 2019-11-21 | Zealand Pharma As | Compuestos agonistas triples de glucagón-glp-1-gip. |
EP3065767B1 (en) | 2013-11-06 | 2020-12-30 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/gip受體促效劑 |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽-4(exendin-4)胜肽類似物 |
TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/升糖素受體促效劑 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
JP2017513875A (ja) * | 2014-04-22 | 2017-06-01 | ティーエックスピー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 分枝状アミノ酸プローブを有するペプチド類似体 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
US10487314B2 (en) | 2014-06-26 | 2019-11-26 | The Trustees Of Columbia University In The City Of New York | Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells |
RU2573933C1 (ru) | 2014-08-21 | 2016-01-27 | Дафот Энтерпрайсис Лимитед | Пептид для лечения сахарного диабета 2-го типа и его осложнений |
CA2965732A1 (en) | 2014-10-29 | 2016-05-06 | Zealand Pharma A/S | Gip agonist compounds and methods |
JP6989385B2 (ja) | 2015-04-16 | 2022-01-05 | ジーランド ファーマ アクティーゼルスカブ | アシル化グルカゴン類似体 |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
JP6563614B1 (ja) | 2016-12-09 | 2019-08-21 | ジーランド・ファーマ・ア/エス | アシル化glp−1/glp−2二重アゴニスト |
CN109679964A (zh) * | 2019-01-12 | 2019-04-26 | 青岛华义宏博生物科技有限公司 | 一种表达人胰岛素基因的重组乳酸乳球菌 |
EP3938037A1 (en) | 2019-03-15 | 2022-01-19 | Diet4Life ApS | Combination of dietary peptides |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
AU4114493A (en) * | 1992-04-24 | 1993-11-29 | Polymer Technology Group, Inc., The | Method of culturing viable cells and method of regulating the level of a compound in a body fluid |
JP2575298B2 (ja) | 1992-06-15 | 1997-01-22 | フアイザー・インコーポレイテツド | グルカゴン様ペプチド及びインシュリノトロピン誘導体 |
HU225496B1 (en) | 1993-04-07 | 2007-01-29 | Scios Inc | Pharmaceutical compositions of prolonged delivery, containing peptides |
US5424286A (en) * | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
CA2137206A1 (en) | 1993-12-09 | 1995-06-10 | John A. Galloway | Glucagon-like insulinotropic peptides, compositions and methods |
GB9409496D0 (en) * | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
CA2262647C (en) * | 1996-08-08 | 2007-12-04 | Amylin Pharmaceuticals, Inc. | Methods for regulating gastrointestinal motility |
EP1056774A1 (en) | 1998-02-27 | 2000-12-06 | Novo Nordisk A/S | N-terminally truncated glp-1 derivatives |
EP1932535A3 (en) | 1998-07-31 | 2008-10-29 | Novo Nordisk A/S | Stimulation of beta cell profileration |
-
1999
- 1999-08-10 CA CA002339326A patent/CA2339326A1/en not_active Abandoned
- 1999-08-10 DK DK99942066.4T patent/DK1105460T3/da active
- 1999-08-10 AU AU55524/99A patent/AU776514B2/en not_active Ceased
- 1999-08-10 JP JP2000565103A patent/JP4624558B2/ja not_active Expired - Fee Related
- 1999-08-10 ES ES99942066T patent/ES2335066T3/es not_active Expired - Lifetime
- 1999-08-10 ES ES08019260.2T patent/ES2553108T3/es not_active Expired - Lifetime
- 1999-08-10 EP EP08019260.2A patent/EP2028269B1/en not_active Expired - Lifetime
- 1999-08-10 EP EP99942066A patent/EP1105460B1/en not_active Expired - Lifetime
- 1999-08-10 DE DE69941510T patent/DE69941510D1/de not_active Expired - Lifetime
- 1999-08-10 US US09/762,538 patent/US7056734B1/en not_active Expired - Fee Related
- 1999-08-10 AT AT99942066T patent/ATE445006T1/de active
- 1999-08-10 WO PCT/US1999/018099 patent/WO2000009666A2/en active IP Right Grant
-
2006
- 2006-04-07 US US11/400,715 patent/US20070041951A1/en not_active Abandoned
-
2007
- 2007-04-24 JP JP2007114374A patent/JP4755133B2/ja not_active Expired - Fee Related
-
2009
- 2009-08-07 JP JP2009184807A patent/JP2009291206A/ja active Pending
-
2011
- 2011-04-05 JP JP2011083828A patent/JP2011177181A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ATE445006T1 (de) | 2009-10-15 |
AU5552499A (en) | 2000-03-06 |
DE69941510D1 (de) | 2009-11-19 |
US20070041951A1 (en) | 2007-02-22 |
US7056734B1 (en) | 2006-06-06 |
WO2000009666A2 (en) | 2000-02-24 |
EP1105460A2 (en) | 2001-06-13 |
CA2339326A1 (en) | 2000-02-24 |
WO2000009666A3 (en) | 2000-11-23 |
EP2028269B1 (en) | 2015-10-21 |
JP4624558B2 (ja) | 2011-02-02 |
JP4755133B2 (ja) | 2011-08-24 |
JP2002522068A (ja) | 2002-07-23 |
ES2335066T3 (es) | 2010-03-18 |
AU776514B2 (en) | 2004-09-09 |
EP2028269A1 (en) | 2009-02-25 |
WO2000009666A9 (en) | 2000-07-13 |
JP2009291206A (ja) | 2009-12-17 |
EP1105460B1 (en) | 2009-10-07 |
JP2007209348A (ja) | 2007-08-23 |
ES2553108T3 (es) | 2015-12-04 |
JP2011177181A (ja) | 2011-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1105460T3 (da) | Differentiering af ikke-insulinproducerende celler til insulinproducerende celler med GLP-1 eller Exendin-4 og anvendelser deraf | |
YU59392A (sh) | A-b-c proinsulin, postupak dobijanja i intermedijeri u proizvodnji insulina | |
WO2003014318A3 (en) | Methods for treating diabetes and other blood sugar disorders | |
DK0670896T3 (da) | Kloning og ekspression af biologisk aktivt alfa-galactosidase A | |
ATE216427T1 (de) | Verfahren zur herstellung von polypeptidabkömmlingen | |
AU5027299A (en) | Use of glp-1 and analogues for preventing type ii diabetes | |
DE69119454T2 (de) | DNA-Fragment, das ein Polypeptid mit Nitrilhydrataseaktivität kodiert, DNA-Fragment enthaltende Transformante und Verfahren zur Herstellung von Amiden unter Verwendung der Transformante | |
NO985231D0 (no) | Forbindelser som fremmer vevsvekst | |
AU1672388A (en) | Expression of human proapolipoprotein a-i | |
GB2370275B (en) | Introducing double stranded RNA into nematodes | |
MY119174A (en) | Process for the production of chemically prestressed glass, and the use thereof | |
DE3583194D1 (de) | Verfahren zur herstellung von einem polypeptid mittels eines transformierten mikroorganismus, ein dazu geeigneter transformierter mikroorganismus, und zur herstellung dieser mikroorganismen geeignete dns sequenzen. | |
ATE264869T1 (de) | Glucagonähnliche, insulinotrope komplexe, ihre zusammensetzungen und ihr herstellungsverfahren | |
ATE231727T1 (de) | Zusammensetzung für verbesserung der pankreasfunktion | |
ATE116348T1 (de) | Verfahren zur zubereitung beständiger bitumen- polymermischungen. | |
HU895573D0 (en) | Process for producing human fibroblast growth factor derivatives | |
DE59807382D1 (de) | Mutanten der Formiatdehydrogenase aus Candida biodinii, Gensequenzen diese codierend sowie Verwendung dieser Formiatdeydrogenasen | |
ATE335750T1 (de) | Verfahren zur herstellung von organosilylalkylpolysulfanen | |
DE3854420T2 (de) | Onkogen kodierendes polypeptid, das wachstumsfaktoraktivität besitzt, verfahren zu seiner herstellung und verwendung. | |
DK0672124T3 (da) | Anvendelse af en DNA-sekvens, der koder for et oxalsyre-nedbrydende protein i form af et selektionsgen | |
DK0440989T3 (da) | Fremgangsmåde til fremstilling af et tørret præparat indeholdende insulin-lignende vækstfaktor I (IGF-I) | |
EP0266878A3 (en) | Chemical compounds | |
DK1126858T3 (da) | Produktion af en biologisk faktor og skabelse af et immunologisk privilegeret miljø ved anvendelse af genetisk ændrede Sertoliceller | |
DE60021240D1 (de) | Verfahren zur Herstellung von Zement mit niedrigem Chromgehalt | |
DE602005024974D1 (de) | Polypeptid mit einer Delta-5-Fettsäure-Desaturierungsaktivität, für das Polypeptid codierendes Polynukleotid und Verwendung davon. |